Skip to content
Disclosery

Aquilo Capital Management, LLC

Follow

13F filer, CIK 1591986, SAN FRANCISCO, CA

Aquilo Capital Management, LLC reported $160,453,237 across 10 holdings for the quarter ended 2023-12-31, in a 13F-HR filed 2024-02-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001591986-24-000002

Period
2023-12-31
Reported value
$160M
Holdings
10
Top 10 weight
100%
New
3
Sold out
5

Largest buys vs the previous quarter

SecurityShares changeApprox. value
REPARE THERAPEUTICS INCnew+633,271$4.62M
KYMRadded+99,118$2.52M
SUTRO BIOPHARMA INCnew+420,649$1.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
BLUEPRINT MEDICINES CORPreduced-124,263-$11.5M
SLNreduced-268,949-$4.67M
CCCCexited-1,990,334-$3.7M
MERUS N Vreduced-75,000-$2.06M
GMABexited-52,148-$1.84M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2023

Share positions as resolved from 13F-HR 0001591986-24-000002, largest first. % of portfolio is the value over $142,595,237, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 908,474 shares 908,474$27.8M19.5%0Timeline
BLUEPRINT MEDICINES CORPBLUEPRINT MEDICINES CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 254,827 shares 254,827$23.5M16.48%-124,263
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 881,337 shares 881,337$22.4M15.74%+99,118Timeline
ARVNARVINAS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 489,153 shares 489,153$20.1M14.12%0Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 1,043,284 shares 1,043,284$18.1M12.71%-268,949Timeline
RGNXREGENXBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 802,424 shares 802,424$14.4M10.1%-45,000Timeline
MERUS N VMERUS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 355,109 shares 355,109$9.77M6.85%-75,000
REPARE THERAPEUTICS INCREPARE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 633,271 shares 633,271$4.62M3.24%new
SUTRO BIOPHARMA INCSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: restricted; 2023Q2: restricted; 2023Q3: restricted; 2023Q4: 420,649 shares 420,649$1.8M1.27%new

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
XBISPDR SERIES TRUST S&P BIOTECHput200,000$17.9Mnew

Sold out in Q4 2023

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CCCCC4 THERAPEUTICS INC1,990,334$3.7Mshares
GMABGENMAB A/S52,148$1.84Mshares
ARGXARGENX SE3,715$1.83Mshares
OLMAOLEMA PHARMACEUTICALS INC88,875$1.1Mshares
PIERIS PHARMACEUTICALS INCPIERIS PHARMACEUTICALS INC3,303,190$984Kshares

How Q4 2023 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001591986-24-000002 base2024-02-14acceptance time not in the bulk data set